This petition was submitted during the 2010 to 2015 Parliament
Closed petition Call for reassessment of the Cancer Drugs Fund for blood cancer patients
Closed on
This is a petition on behalf of blood cancer patients who are concerned about the recent changes made to the Cancer Drugs Fund.
It was announced on Monday, January 12, 2015, that life-extending cancer drugs are to be removed from a list of medicines that are approved for funding via the Cancer Drugs Fund.
This petition calls specifically for a rethink over the de-listing of the following drugs:
Bosutinib and Dasatinib for blast-phase Chronic Myeloid Leukaemia;
The de-listing of Bortezomib for relapsed Myeloma, Mantle-Cell Lymphoma and Waldenstrom Macroglobulinemia;
The de-listing of Bendamustine for non-Hodgkin Lymphoma;
The de-listing of Ofatumumab for relapsed or refractory Chronic Lymphatic Leukaemia;
A re-analysis of the decision to reject Vemurafenib for all Hairy Cell Leukaemia patients and also a re-analysis of the rejection of Idelalisib for Chronic Lymphatic Leukaemia.
730 signatures
Petition progress
View all updates for this petition, with the most recent first.
-
Petition closed
-
Petition published
This petition can now be signed.
If this petition gets 10,000 signatures, government will respond to it.
If this petition gets 100,000 signatures, it will be considered for debate in Parliament.
This petition will stay open until 30 March 2015.